[PRNewswire] Seragon Announces RESTORIN(R), the Most Advanced Anti-Aging
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Nutraceutical to Date
(IRVINE, Calif., Jan. 19, 2023 PRNewswire=연합뉴스) Seragon Biosciences, Inc. today announced the launch of RESTORIN(R), an advanced nutraceutical for healthy aging. RESTORIN integrates a series of patented technologies from Harvard University, Mayo Clinic, and Scripps Research to boost cellular nicotinamide adenine dinucleotide (NAD+) levels and enhance senolytic stimulation.
For decades, the intricate nature of aging has left scientists with many stones unturned in the field of aging intervention. The latest research has pinpointed senolytics and NAD+ as key technologies to address this challenge. RESTORIN is a controlled-release senolytic NAD+ booster. It also utilizes Seragon's SERC™ targeted release technology that implements hydrophilic and lipophilic vehicles and a pH-responsive enteric delivery system to enhance ingredient bioavailability.
RESTORIN contains a series of proprietary forms of senolytic agents, NAD+ precursors, and sirtuin-activating compounds (STACs). Senolytics are molecules that target senescent cells - cells that promote aging and contribute to organ deterioration. NAD+ is a life-preserving coenzyme that enhances cellular energy metabolism and DNA integrity and is the fuel for sirtuins - longevity proteins vital to cellular health.
"There are many studies that point to these molecules having a positive impact on aging and aging-related health conditions, but, so far, no one has been able to combine them at an optimal ratio to achieve a synergistic effect," said David Brown, Ph.D., a senior scientist at Seragon who helped develop RESTORIN. "We've been able to develop advanced forms of these molecules and a series of complex combinations to combat aging, using the best science we have. This is truly a game-changer."
Decades of research have demonstrated that NAD+ levels significantly decline with aging, increasing our susceptibility to a myriad of age-related health conditions ranging from diabetes to neurodegeneration. Replenishing NAD+ levels is critical to thwarting aging. However, it has been challenging to effectively enhance NAD+ at the cellular level through oral delivery.
"In the field of aging, a critical issue to resolve is how to deliver NAD+ precursors in a way that best boosts cellular NAD+ to achieve healthier aging," said Dr. Brown. "We believe that RESTORIN has achieved best-in-class performance in this regard, which is truly a breakthrough. Especially when you consider recent studies showing an increase in NAD+ can even make immunotherapies against cancer more effective, it's very exciting to be a part of this development."
"It's very thrilling to see aging research advancing ways to help people age slower, better, and healthier," he added.
RESTORIN is available to consumers exclusively through its official website, www.restorin.com.
About Seragon Biosciences
Seragon Biosciences, Inc., headquartered in Irvine, California, is a research-based biopharmaceutical company dedicated to improving human and animal health through innovative science. Seragon Biosciences is committed to applying cutting-edge scientific and technological advancements to the fields of aging, metabolism, gene therapy, and bioinformatics. From the research end to consumer products and clinical applications, Seragon strives to bring people access to the most significant breakthroughs in medicine. For more information, please visit www.seragon.com.
Logo - https://mma.prnewswire.com/media/1986399/Seragon_Logo.jpg
Seragon Biosciences is a research-based biopharmaceutical company dedicated to improving human and animal health through innovative science.
Photo - https://mma.prnewswire.com/media/1986400/Seragon_Pharmaceuticals_RESTORIN.jpg
RESTORIN is an advanced senolytic NAD+ booster designed to promote healthy aging.
Source: Seragon Biosciences
[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 미국 이어 한국도 '북한군 전투참여' 공식화…정부대응 주목(종합2보) | 연합뉴스
- '트럼프 쇼크'에 환율 1,410선 뚫렸다…코스피 2,410대로 밀려(종합) | 연합뉴스
- 의협 비대위원장에 '전공의지지' 박형욱 "시한폭탄 멈춰야 대화" | 연합뉴스
- 국방엔 폭스앵커, '효율부' 수장엔 머스크…트럼프 인선 속도전(종합) | 연합뉴스
- '구속 갈림길' 명태균·김영선…검찰, 공천 개입 의혹 수사 확대 | 연합뉴스
- 충격의 만루포 허용…믿었던 고영표, 대만전 2이닝 6실점 | 연합뉴스
- 문다혜, 제주 단독주택 불법 숙박업 인정…15일 검찰 송치(종합) | 연합뉴스
- [수능 D-1] "공부한 거 다 나오고, 쓰면 정답이길"…수험생들 예비소집 | 연합뉴스
- 이재명 선거법 선고 생중계 불허 "법익 고려"…법원 보안 강화(종합2보) | 연합뉴스
- 신임 주한 중국대사에 다이빙 주유엔 부대사 내정(종합) | 연합뉴스